A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Phase 1
421
about 9.7 years
18+
15 sites in CA, FL, GA +5
About this study
Researchers are testing a treatment called LY4257496 alone and with standard cancer treatments in people with certain types of advanced cancers. The trial will last up to 36 weeks or until the cancer progresses.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take LY4257496
- 2.Take Standard of Care Anticancer Therapies
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Phase 1a Dose Escalation: Maximum Tolerated Dose of LY4257496, Phase 1b Dose Expansion and Optimization: Objective Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)
Secondary: Phase 1a Dose Escalation PK: Area Under the Curve (AUC) of LY4257496, Phase 1a Dose Escalation Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY4257496, Phase 1a Dose Escalation and Optimization PK: AUC of LY4257529, Phase 1a Dose Escalation and Optimization PK: Cmax of LY4257529, Phase 1a Dose Escalation and Optimization: ORR: Percentage of Participants with Best Response of CR or PR
Oncology